G H Tofler1, J Massaro2, C J O'Donnell3, P W F Wilson4, R S Vasan5, P A Sutherland6, J B Meigs7, D Levy6, R B D'Agostino2. 1. Royal North Shore Hospital, Sydney University, Australia. Electronic address: Geoffrey.Tofler@health.nsw.gov.au. 2. Boston University, United States. 3. The Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health, United States; The Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States; Massachusetts General Hospital, United States. 4. Emory University, United States. 5. The Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health, United States. 6. The Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health, United States; The Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States. 7. Massachusetts General Hospital, United States.
Abstract
INTRODUCTION: Although plasminogen activator inhibitor (PAI-1) plays a key regulatory role in fibrinolysis, it has not been clearly shown to independently predict cardiovascular disease (CVD) among individuals without prior CVD. We investigated, in the Framingham Heart Study offspring cohort, whether PAI-1 predicted CVD risk among individuals without prior CVD. METHODS: Plasma PAI-1 antigen and tissue plasminogen activator (TPA) antigen were measured in 3203 subjects without prior CVD between 1991 and 1995; average follow-up of 10 years. PAI-1 was remeasured 4 years after baseline, to determine the effect of serial change on risk. RESULTS: PAI-1 levels (mean ± SD) were 29.1 ng/ml (19.2) versus 22.1 (16.5) for those and without incident CVD; p<0.001, and TPA levels were 12.0 ng/ml (5.7) versus 9.0 (4.7); p<0.001. PAI-1 and TPA antigen levels had a strong unadjusted linear relation with incident CVD (p<0.001). After adjustment for conventional risk factors, the hazard ratios (HRs) for higher quartiles of PAI-1, compared with the lowest, were 1.9, 1.9, 2.6 (linear trend p=0.006), and 1.6, 1.6, 2.9 (p<0.001) for TPA antigen. The adjusted HRs for increasing quartiles of serial change in PAI-1 at 4 years, compared with the lowest, were 0.9, 0.8, 1.3 (p=0.050). C statistic assessment showed that adding PAI-1 or TPA to conventional risk factors resulted in small increases in discrimination and modest reclassification of risk, which was statistically significant for TPA (net reclassification 6.8%, p=0.037) but not PAI-1 (4.8%, p=0.113). CONCLUSION: PAI-1 and TPA antigen levels are predictive of CVD events after accounting for established risk factors. A serial increase in PAI-1 is associated with a further increase in risk. These findings support the importance of fibrinolytic potential in CVD.
INTRODUCTION: Although plasminogen activator inhibitor (PAI-1) plays a key regulatory role in fibrinolysis, it has not been clearly shown to independently predict cardiovascular disease (CVD) among individuals without prior CVD. We investigated, in the Framingham Heart Study offspring cohort, whether PAI-1 predicted CVD risk among individuals without prior CVD. METHODS: Plasma PAI-1 antigen and tissue plasminogen activator (TPA) antigen were measured in 3203 subjects without prior CVD between 1991 and 1995; average follow-up of 10 years. PAI-1 was remeasured 4 years after baseline, to determine the effect of serial change on risk. RESULTS:PAI-1 levels (mean ± SD) were 29.1 ng/ml (19.2) versus 22.1 (16.5) for those and without incident CVD; p<0.001, and TPA levels were 12.0 ng/ml (5.7) versus 9.0 (4.7); p<0.001. PAI-1 and TPA antigen levels had a strong unadjusted linear relation with incident CVD (p<0.001). After adjustment for conventional risk factors, the hazard ratios (HRs) for higher quartiles of PAI-1, compared with the lowest, were 1.9, 1.9, 2.6 (linear trend p=0.006), and 1.6, 1.6, 2.9 (p<0.001) for TPA antigen. The adjusted HRs for increasing quartiles of serial change in PAI-1 at 4 years, compared with the lowest, were 0.9, 0.8, 1.3 (p=0.050). C statistic assessment showed that adding PAI-1 or TPA to conventional risk factors resulted in small increases in discrimination and modest reclassification of risk, which was statistically significant for TPA (net reclassification 6.8%, p=0.037) but not PAI-1 (4.8%, p=0.113). CONCLUSION:PAI-1 and TPA antigen levels are predictive of CVD events after accounting for established risk factors. A serial increase in PAI-1 is associated with a further increase in risk. These findings support the importance of fibrinolytic potential in CVD.
Authors: A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans Journal: Circulation Date: 1998-11-24 Impact factor: 29.690
Authors: S Ye; F R Green; P Y Scarabin; V Nicaud; L Bara; S J Dawson; S E Humphries; A Evans; G Luc; J P Cambou Journal: Thromb Haemost Date: 1995-09 Impact factor: 5.249
Authors: J Schneiderman; M S Sawdey; M R Keeton; G M Bordin; E F Bernstein; R B Dilley; D J Loskutoff Journal: Proc Natl Acad Sci U S A Date: 1992-08-01 Impact factor: 11.205
Authors: Peter M Okin; Richard B Devereux; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Markku S Nieminen; Steven Snapinn; Katherine E Harris; Peter Aurup; Jonathan M Edelman; Hans Wedel; Lars H Lindholm; Björn Dahlöf Journal: JAMA Date: 2004-11-17 Impact factor: 56.272
Authors: Penny M Kris-Etherton; Paul W Stewart; Henry N Ginsberg; Russell P Tracy; Michael Lefevre; Patricia J Elmer; Lars Berglund; Abby G Ershow; Thomas A Pearson; Rajasekhar Ramakrishnan; Stephen F Holleran; Barbara H Dennis; Catherine M Champagne; Wahida Karmally Journal: J Nutr Date: 2020-08-01 Impact factor: 4.798
Authors: Omar Bayomy; Ajay D Rao; Rajesh Garg; Anand Vaidya; Alyssa R Kotin; Beata Reiber; Stephanie Nijmeijer; Marcelo F Di Carli; Michael Jerosch-Herold; Raymond Y Kwong; Gail K Adler Journal: Metab Syndr Relat Disord Date: 2017-05-15 Impact factor: 1.894
Authors: Tatsiana Beiko; Michael G Janech; Alexander V Alekseyenko; Carl Atkinson; Harvey O Coxson; Jeremy L Barth; Sarah E Stephenson; Carole L Wilson; Lynn M Schnapp; Alan Barker; Mark Brantly; Robert A Sandhaus; Edwin K Silverman; James K Stoller; Bruce Trapnell; Strange Charlie Journal: Chronic Obstr Pulm Dis Date: 2017-07-15
Authors: Caitlin G Howe; Zhigang Li; Michael S Zens; Thomas Palys; Yu Chen; Jacqueline Y Channon; Margaret R Karagas; Shohreh F Farzan Journal: J Nutr Date: 2017-10-25 Impact factor: 4.798
Authors: Jacob J Russell; Laurel A Grisanti; Scott M Brown; Chastidy A Bailey; Shawn B Bender; B Chandrasekar Journal: Cell Signal Date: 2021-03-27 Impact factor: 4.850
Authors: Abdou Mousas; Georgios Ntritsos; Ming-Huei Chen; Ci Song; Jennifer E Huffman; Ioanna Tzoulaki; Paul Elliott; Bruce M Psaty; Paul L Auer; Andrew D Johnson; Evangelos Evangelou; Guillaume Lettre; Alexander P Reiner Journal: PLoS Genet Date: 2017-08-07 Impact factor: 5.917
Authors: Katherine A Moon; Ana Navas-Acien; Maria Grau-Pérez; Kevin A Francesconi; Walter Goessler; Eliseo Guallar; Jason G Umans; Lyle G Best; Jonathan D Newman Journal: PLoS One Date: 2017-08-03 Impact factor: 3.240